JPRN-UMIN000027629
Completed
Phase 2
A single arm confirmatory study of pembrolizumab in patients with previously untreated advanced sarcomatoid carcinoma of the lung - A confirmatory study of pembrolizumab in patients with advanced sarcomatoid carcinoma of the lung
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital0 sites22 target enrollmentJune 12, 2017
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
- Enrollment
- 22
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Active auto\-immune disease 2\. Interstitial lung disease or pulmonary fibrosis 3\. Active infection such as bacteria, HBV, or HCV
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Clinical trial of combined therapy with pembrolizumab and lenvatinib for patients with classic Kaposi sarcoma treated with at least one previous line of chemioterapy.2024-512834-14-00Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico25
Active, not recruiting
Phase 1
Study on Pembrolizumab in preneoplastic high grade HPV-related vulvar and cervical lesionsPatients with pre neoplastic high grade HPV-related vulvar and cervical lesionsMedDRA version: 20.0Level: PTClassification code 10054932Term: Vulvar dysplasiaSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: PTClassification code 10008263Term: Cervical dysplasiaSystem Organ Class: 10038604 - Reproductive system and breast disordersTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-002247-23-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE46
Active, not recruiting
Phase 1
A Phase II Study of Pembrolizumab in Subjects with Gastric CancerGastric CancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003574-16-FRMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.270
Active, not recruiting
Phase 1
A Phase II Study of Pembrolizumab in Subjects with Gastric CancerGastric CancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003574-16-LTMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.253
Active, not recruiting
Phase 1
A Phase II Study of Pembrolizumab in Subjects with Gastric CancerGastric cancerMedDRA version: 20.0Level: PTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003574-16-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.315